HPLC Analysis for Simultaneous Determination of Atorvastatin and Ezetimibe in Pharmaceutical Formulations

Abstract

A simple, isocratic, and sensitive reverse phase high performance liquid chromatographic (RP‐LC) method has been developed, for the first time, for quantitative determination of atorvastatin and ezetimibe in pharmaceutical formulations. Atorvastatin and ezetimibe were chromatographed using 0.01 M ammonium acetate buffer (pH∶3.0): Acetonitrile (50∶50 v/v) as mobile phase. The detection was monitored at 254 nm. The retention times of ezetimibe and atorvastatin were 15.50±0.07 and 19.30±0.06, respectively. The linearity of the method was studied over the concentration range of 4–400 µg/mL for atorvastatin and 5–500 µg/mL for ezetimibe. The limit of detection for atorvastatin and ezetimibe were found as 1.25 µg/mL and 1.48 µg/mL, respectively. The proposed method was applied for the quantitative determination of atorvastatin and ezetimibe in commercial combination formulations.